AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JAN 16 - (NewsRx.com & NewsRx.net) -- A team of researchers in Japan has studied the potential role of ETS-1 as an angiogenic mediator in uterine, endometrial, and cervical cancers. They presented their findings in two studies published in the Annals of Oncology.
"Angiogenesis is essential for development, growth, and advancement of solid tumors. During angiogenesis, ETS-1 is strongly expressed in vascular endothelial cells and the adjacent interstitial cells, while the inhibition of ETS-1 expression leads to suppression of angiogenesis," wrote J. Fujimoto and colleagues, Gifu University, Japan, in one report (Clinical implications of expression of ETS-1 related to angiogenesis in uterine endometrial cancers. Ann Oncol, 2002;13(10):1605-1611).
The researchers studied "the clinical implications of ETS-1 in relation to angiogenesis in uterine endometrial cancers. ... From the tissues of 60 uterine endometrial cancers, the levels of ets-1 mRNA, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived endothelial cell growth factor (PD-ECGF), and interleukin (IL)-8 were determined by competitive RT-PCR [reverse transcriptase polymerase chain reaction] using recombinant RNA and enzyme immunoassay, and the localization and counts of microvessels were determined by immunohistochemistry."
Fujimoto's group reported "a significant correlation between microvessel count and ets-1 gene expression levels in uterine endometrial cancers. Immunohistochemical staining revealed that the localization of ETS-1 was similar to that of vascular endothelial cells."
"The level of ets-1 mRNA tended to increase with increasing disease stage," they continued. "Furthermore, the level of ets-1 mRNA correlated with levels of VEGF in well-differentiated adenocarcinomas (G1) and of bFGF in moderately differentiated adenocarcinomas (G2) and poorly differentiated adenocarcinomas (G3)."
The researchers therefore concluded that "ETS-1 is a ...